Summary of Key Points Core Viewpoint - Tai Long Pharmaceutical (600222) is planning to issue up to RMB 800 million in short-term financing bonds to replace bank loans and supplement working capital, with a shareholder meeting scheduled for July 17, 2025, to discuss this proposal [1]. Company Performance - As of July 11, 2025, Tai Long Pharmaceutical's stock closed at RMB 6.01, reflecting a 2.91% increase from the previous week's closing price of RMB 5.84 [1]. - The stock reached a weekly high of RMB 6.06 on July 10, 2025, and a low of RMB 5.81 on July 7, 2025 [1]. - The company's current total market capitalization is RMB 3.449 billion, ranking 51st out of 67 in the traditional Chinese medicine sector and 4016th out of 5149 in the A-share market [1]. Financing Plans - The company intends to apply for registration to issue short-term financing bonds with a maximum total of RMB 800 million, with individual bond terms not exceeding 270 days [1]. - The issuance will be conducted in a manner that allows for either a single or multiple issuances within the approved registration limit and validity period [1]. - The funds raised will be used for replacing financial institution loans and supplementing working capital [1]. - The interest rate for the bonds will be determined based on the company's credit rating and market interest rates [1]. - The management team will be authorized to handle the registration, issuance, and related tasks for the short-term financing bonds [1].

Core Points - The company is holding a shareholders' meeting to ensure the protection of investors' rights and the orderly conduct of the meeting [1][2] - The meeting will take place on July 17, 2025, at 14:30 in Zhengzhou, with both on-site and online voting options [2][3] - The agenda includes the election of vote counters, discussion of proposals, and a vote on the issuance of short-term financing bonds [2][4] Group 1: Meeting Organization - A secretariat will be established to manage the meeting and related matters [1] - Only authorized attendees, including shareholders, directors, and legal representatives, will be allowed entry [1][2] - Attendees must register at least ten minutes before the meeting starts [1] Group 2: Meeting Procedures - The meeting will begin with an introduction of participants and the election of vote counters [2] - Shareholders will have the opportunity to ask questions and express their opinions, with a time limit of five minutes per speaker [1][2] - Voting will be conducted through a registered name system and online voting, with results announced afterward [2] Group 3: Proposal for Short-term Financing Bonds - The company plans to apply for the registration and issuance of short-term financing bonds totaling up to 800 million RMB [4] - The bonds will have a maximum term of 270 days and can be issued in one or multiple tranches [3][4] - Proceeds will be used for refinancing bank loans, supplementing working capital, and other approved purposes [4][5] Group 4: Authorization for Issuance - The management is proposed to be authorized to determine the specifics of the bond issuance, including amount, term, and interest rate [5] - The authorization will remain effective until all related matters are completed [5] - The proposal has already been approved by the company's board of directors [5]

河南太龙药业股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 7 月 目 录 | 2025 | 年第二次临时股东大会会议须知 2 | | --- | --- | | 2025 | 年第二次临时股东大会会议议程 3 | | 议案一 | 关于拟申请注册发行超短期融资券的议案 4 | 1 2025 年第二次临时股东大会会议须知 为维护投资者的合法权益，确保本次股东大会顺利进行，河南太 龙药业股份有限公司（以下简称"公司"）根据《中华人民共和国公 司法》《上市公司股东会规则》以及《公司章程》等有关规定，特制 定会议须知如下： 一、本次股东大会设秘书处，负责会议组织工作和处理相关事宜。 二、为保证本次股东大会的严肃性和正常秩序，除依法出席会议 的公司股东（或股东代理人）、董事、监事、高级管理人员、聘请的 律师及相关工作人员外，公司有权依法拒绝其他人士入场。 三、出席会议的股东（或股东代理人）必须在会议召开前十分钟 向大会秘书处办理签到、登记手续。 3 四、股东（或股东代理人）参加股东大会依法享有发言权、质询 权、表决权等权利。股东需要发言或就有关问题进行提问的，应在会 议登记期间向大会秘书处进行登记， ...

Core Viewpoint - The announcement details the provision of guarantees by the company for its wholly-owned and controlling subsidiaries, aimed at supporting their financing needs and promoting business development [1][5]. Summary by Sections Guarantee Overview - The company has provided a guarantee of RMB 6.8 million for its wholly-owned subsidiary, Zhejiang Tongjuntang Traditional Chinese Medicine Co., Ltd., and a guarantee of RMB 4 million for its controlling subsidiary, New Leading (Chongqing) Pharmaceutical Technology Co., Ltd. [1] - The total actual guarantee balance for Zhejiang Tongjuntang is RMB 145 million (including this guarantee), and for Chongqing New Leading, it is RMB 13.57 million (including this guarantee) [1]. Approval Process - The company held board meetings on April 7, 2025, and April 29, 2025, to approve the provision of guarantees for the fiscal year 2025 [2]. - The company adjusted the unused guarantee quota of RMB 40 million from its subsidiary, Zhejiang Tongjuntang, to another subsidiary, Tongjuntang [2]. Financial Status of Guaranteed Entities - Zhejiang Tongjuntang Traditional Chinese Medicine Co., Ltd. has total assets of RMB 492.19 million and total liabilities of RMB 293.63 million, with a net profit of RMB 55.30 million [4]. - New Leading (Chongqing) Pharmaceutical Technology Co., Ltd. has total assets of RMB 25.75 million and total liabilities of RMB 11.99 million, with a net asset value of RMB 13.76 million [4]. Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary to meet the operational and financing needs of the subsidiaries, aligning with the company's development strategy [5]. - The financial condition of the guaranteed entities is stable, and the overall risk is controllable, ensuring no significant impact on the company's daily operations [5]. Board Opinion - The board believes that the guarantees will enhance financing efficiency, reduce costs, and support sustainable business development, considering the subsidiaries' financial stability and creditworthiness [5]. External Guarantee Status - As of the announcement date, the company has no overdue guarantees and maintains a total external guarantee balance without any overdue items [6].

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-031 河南太龙药业股份有限公司 关于拟申请注册发行超短期融资券的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）于 2025 年 7 月 1 日召开第九届董事会第三十二次会议，审议通过了《关于拟申请 注册发行超短期融资券的议案》。为拓宽融资渠道，增加债务融资的 多样性与灵活性，优化融资成本，根据《公司法》《银行间债券市场 非金融企业债务融资工具管理办法》等相关规定，并结合公司实际情 况，公司拟向中国银行间市场交易商协会申请注册发行总额不超过 （含）人民币 8 亿元的超短期融资券，具体情况如下： 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-031 一、本次超短期融资券注册发行方案主要内容 （一）注册和发行规模：拟注册发行规模不超过（含）人民币 8 亿元，具体发行规模将以公司在中国银行间市场交易商协会注册的金 额为准。 （二）发行期限：单期发行期限不超过 270 天（含）。 （三）发行方式 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-029 河南太龙药业股份有限公司 被担保人名称：公司下属全资子公司浙江桐君堂中药饮片有限 公司（以下简称"中药饮片公司"）、下属控股子公司新领先（重庆） 医药科技有限公司（以下简称"重庆新领先"）。 本次担保金额及已实际为其提供的担保余额：本次为中药饮片 公司提供的担保金额为 680 万元，为重庆新领先提供的担保金额为 400 万元。截至本公告日，河南太龙药业股份有限公司（以下简称"公 司"）及下属子公司已实际为中药饮片公司提供的担保余额为 14,500 万元(含本次)，已实际为重庆新领先提供的担保余额为 1,357.05 万 元(含本次)。 本次担保是否有反担保：否 对外担保逾期的累计数量：无 一、担保情况概述 （一）基本情况 1、近日，公司全资子公司桐君堂药业有限公司（以下简称"桐 君堂"）与杭州银行股份有限公司桐庐支行（以下简称"杭州银行桐 关于为下属全资及控股子公司融资提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ...

证券代码：600222 证券简称：太龙药业 公告编号：2025-032 河南太龙药业股份有限公司 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 17 日 至2025 年 7 月 17 日 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 17 日 14 点 30 分 召开地点：郑州市高新技术产业开发区金梭路 8 号公司一楼会议室 股东大会召开日期：2025年7月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-030 河南太龙药业股份有限公司 第九届董事会第三十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 河南太龙药业股份有限公司（以下简称"公司"）第九届董事会 第三十二次会议于 2025 年 7 月 1 日在公司一楼会议室以现场结合通 讯的方式召开。会议通知已于 2025 年 6 月 26 日送达各位董事。本次 会议应出席董事 9 人，实际出席董事 9 人，其中副董事长李景亮先生、 独立董事方亮先生、独立董事刘玉敏女士以通讯方式出席。会议由董 事长尹辉先生召集并主持，监事列席了会议。会议的召集、召开及表 决程序符合有关法律、法规和《公司章程》的规定，所作决议合法有 效。 二、董事会会议审议情况 （一）审议通过《关于拟申请注册发行超短期融资券的议案》 本议案尚需提交公司股东大会审议。 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-030 （二）审议通过《关于召开 2025 年第二次临时股东大会的议案》 ...